---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-26-000032"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2026-05-13T11:00:44+00:00"
generated_at: "2026-05-13T11:15:50.174790+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Avalo reports Q1 net loss $19.6M, Phase 2 HS trial meets endpoints, $431M offering

## Summary
- Phase 2 LOTUS topline: HiSCR75 absolute improvement 42.2% (150mg) and 42.9% (300mg) vs placebo 25.6%; p=0.018 and 0.015.
- Q1 2026 net loss $19.6M ($0.98 loss/share) vs $13.1M prior year, driven by higher R&D costs.
- Cash $82.0M as of Mar 31, 2026; subsequent public offering raised gross $431.3M (net $405M), extending runway into 2029.
- Milestone Buyout Option: paid $2.25M for option to replace $15M milestone with $5.125M payment upon Phase 3 start.
- R&D expense $14.0M (+$4.9M YoY); G&A $6.9M (+$1.3M YoY).

## SEC filing metadata
- accession: 0001534120-26-000032
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2026-05-13T11:00:44+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000032/0001534120-26-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000032/avtx-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-26-000032
- JSON: https://secwatch.observer/filing/0001534120-26-000032.json
- Plain text: https://secwatch.observer/filing/0001534120-26-000032.txt

## Key facts
- Earnings Releases
  Avalo Therapeutics, Inc. reported first quarter 2026 results: net income Net loss was $19.6 million, EPS Basic and diluted net loss per share was $0.98.
  - Period: first quarter 2026
  - Net income: Net loss was $19.6 million
  - EPS: Basic and diluted net loss per share was $0.98
  - Result: reported results
  source text: On May 13, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000032/0001534120-26-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.